Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage IIIB-C or Stage IV Melanoma By Ogkologos - February 2, 2026 440 0 Facebook Twitter Google+ Pinterest WhatsApp Final data from the CheckMate 238 study Source RELATED ARTICLESMORE FROM AUTHOR Beginning Surveillance Colonoscopy After 5 Years from Removal of High-Risk Adenomas Non-inferior than at 3 Years in Terms of Cumulative CRC Incidence Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce MOST POPULAR EMA Recommends Extension of Indications for Atezolizumab September 28, 2020 Study Provides Closer Look at Postmenopausal Bleeding and Endometrial Cancer August 29, 2018 Reflections from our chief scientist: The rise of the whole organism February 4, 2022 Liquid Biopsies on the Horizon for Children with Solid Cancers April 11, 2023 Load more HOT NEWS European Parliament Adopts Its Position on the Critical Medicines Act, Strengthening... Consistent Efficacy Benefit with Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients... Michelle Mitchell: Cancer is a fixable problem Targeted Therapy Based on Molecular Profiling of Malignant Mesothelioma Tumours Is...
